PharmaBCine Inc. (208340) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PharmaBCine Inc. (208340:KRX), powered by AI.
- Current Price
- ₩115
- P/E Ratio
- -1.2
- Market Cap
- 9.2B
- Sector
- Healthcare
What is the PharmaBCine Inc. stock price forecast?
PharmaBCine Inc. is currently trading at ₩115. View real-time AI analysis on Alpha Lenz.
What is PharmaBCine Inc. insider trading activity?
View the latest insider trading data for PharmaBCine Inc. on Alpha Lenz.
What is PharmaBCine Inc.'s P/E ratio?
PharmaBCine Inc.'s P/E ratio is -1.2.
PharmaBCine Inc.
KRX · 208340“PharmaBCine Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -15.3%. 3Y revenue CAGR of 285.7% highlights clear growth momentum.”
Ask for details →Company Overview
PharmaBCine Inc. is a biotechnology company dedicated to the research, development, and commercialization of novel therapeutics targeting various complex diseases. Its primary function is to drive innovative drug discovery and development processes, utilizing advanced technologies such as antibody engineering and bioconjugation. The company primarily focuses on oncology, leveraging its proprietary platform to develop next-generation cancer treatments. With a commitment to improving global health outcomes, PharmaBCine Inc. collaborates with academic institutions, research bodies, and industry partners to accelerate its therapeutic breakthroughs. In the financial market, the company plays a significant role in the biotechnology sector, contributing to medical innovation and offering potential growth opportunities within the healthcare investment landscape.
Company Statistics
FY 2024Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“PharmaBCine Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -15.3%. 3Y revenue CAGR of 285.7% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
PharmaBCine Inc. (ticker: 208340) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 44 employees. Market cap is $9.2B.
The current price is ₩115 with a P/E ratio of -1.24x and P/B of 0.13x.
ROE is -15.32% and operating margin is -198.51%. Annual revenue is $3.9B.